C3 and viral infectious disease: Complement activation accelerates the severe progression of certain viral infections, and targeted complement therapy has emerged as a promising treatment strategy.[38, 39, 40] C3 inhibitor AMY‐101 showed promising efficacy in clinical trials for severe COVID‐19,[41, 42] but its effectiveness in SFTS treatment requires further study.